Nuclear Receptor Networks in Mucosal Immune Regulation
Project Number6U01AI163063-02
Contact PI/Project LeaderSUNDRUD, MARK SCOTT Other PIs
Awardee OrganizationUNIVERSITY OF FLORIDA
Description
Abstract Text
Project Summary
The gut is a major immunological organ where host-microbe interactions shape both local and systemic immune
tolerance. However, current views of intestinal immune regulation ignore fundamental differences in the function
and metabolite composition of the two distinct organs that comprise the gut—the small and large intestine (or SI
and LI). This impedes a more detailed understanding of immune regulatory mechanisms along the intestinal
tract, and limits efforts to develop safer, more targeted treatments for the two major forms of human inflammatory
bowel diseases (IBDs), ulcerative colitis and small bowel Crohn’s disease. We hypothesize that mucosal CD4 T
cells use different sets of ligand-regulated nuclear receptors (NRs) in the SI and LI to control key regulatory
functions, including IL-10 expression, to local concentration gradients of bile- and microbe-derived metabolites.
On one hand, we have discovered that Foxp3– effector (Teff) subsets in the SI—including Th1 and Th17 cells—
utilize the nuclear xenobiotic receptor, constitutive androstane receptor (CAR/Nr1i3), to direct a ‘hepatocyte-like’
transcriptional response to contend with high local bile acid (BA) concentrations, which are far greater in SI than
in LI (millimolar vs micromolar) due to ‘enterohepatic’ circulation—where primary BAs synthesized in the liver,
stored in the gallbladder, and secreted into the duodenum are actively reabsorbed by specialized enterocytes in
the ileum for portal recirculation to the liver. Because BAs are lipophilic, they can be toxic and pro-inflammatory,
and several nuclear receptors—including CAR—have evolved to suppress BA toxicity. These studies suggest
that enterohepatic circulation establishes a unique SI microenvironment that is distinct from that in the LI and
requires unique transcriptional machinery to protect T cells in the SI. Conversely, the LI harbors 103-107 times
more bacteria than SI, and ~1000-fold lower BA concentrations. Accordingly, microbes and their metabolites—
short chain fatty acids (SCFAs; e.g., butyrate), secondary BAs (produced via microbial metabolism of residual
primary BAs)—are central to immune regulation in the LI. SCFAs inhibit histone deacetylase enzymes (HDACs)
and stabilize Foxp3 gene expression in peripherally-induced T regulatory cells (iTregs), whereas secondary BAs
appear to promote regulatory functions of RORgt+ Tregs in the LI through another NR, vitamin D receptor (VDR).
Thus, while antigens from the enteric flora prime both pro- and anti-inflammatory T cell responses throughout
the gut, marked concentration gradients of bile- and bacteria-derived metabolites in the SI vs. LI are sensed by
different NRs to execute compartmentalized T cell regulatory functions. In testing this hypothesis, we will apply
cutting-edge genomics and computational approaches to comprehensively map the contributions of each of the
49 mouse NRs to specialized regulatory functions in the SI and LI in vivo, using IL-10 expression as the primary
screening target. We will also interrogate the regulation and molecular functions of two key NRs, CAR/Nr1i3 and
VDR/Nr1i1, in SI type 1 regulatory (Tr1) and LI iTreg cells, respectively. These studies will advance
understanding of lymphocyte specialization in the gut, and inform new approaches to treat IBDs.
Public Health Relevance Statement
Project Narrative
The gut is a key immunological organ, where host-microbe interactions shape both local and systemic immune
tolerance. Prevailing immunological views conflate the two organs that comprise the gut—the small and large
intestines (or SI and LI)—yet recent evidence from our labs, and others, suggest that T cells infiltrating the SI
and LI utilize unique sets of ligand-regulated nuclear receptors (NRs) to tether key regulatory functions, including
IL-10 expression, to discrete bile- and microbe-derived metabolite classes. In this proposal, we use both agnostic
and targeted approaches to interrogate the mechanisms by which NRs execute T cell regulatory functions in the
SI vs. LI, thus laying a foundation for understanding compartmentalized immune regulation in the gut.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
969663814
UEI
NNFQH1JAPEP3
Project Start Date
30-July-2021
Project End Date
30-April-2026
Budget Start Date
02-April-2022
Budget End Date
30-April-2022
Project Funding Information for 2021
Total Funding
$2
Direct Costs
$1
Indirect Costs
$1
Year
Funding IC
FY Total Cost by IC
2021
National Institute of Allergy and Infectious Diseases
$2
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 6U01AI163063-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 6U01AI163063-02
Patents
No Patents information available for 6U01AI163063-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 6U01AI163063-02
Clinical Studies
No Clinical Studies information available for 6U01AI163063-02
News and More
Related News Releases
No news release information available for 6U01AI163063-02
History
No Historical information available for 6U01AI163063-02
Similar Projects
No Similar Projects information available for 6U01AI163063-02